Navigation Links
Sigma-Aldrich Announces SAGE(TM) Priority Partners Program; Seeks Researchers to Evaluate New Knockout Rat Models
Date:10/20/2009

ST. LOUIS, Oct. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich® (Nasdaq: SIAL) today announced the launch of the SAGE(TM) Priority Partners Program, through which the Company plans to build a network of researchers to evaluate the 'knockout' rat models it is developing to support pre-clinical research work across a number of medical fields, including Neurobiology, Toxicology, Cardiology, Immunology and others.

The partner program, managed by Sigma Advanced Genetic Engineering (SAGE(TM)) Labs, a Sigma® Life Science initiative based in St. Louis, MO., effectively aims to validate the Company's portfolio of genetically-engineered rodent research models, developed using Sigma-Aldrich's proprietary CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology, which enables scientists to deactivate or 'knockout' specific genes that are associated with human disease.

Partners will be asked to conduct their own evaluation studies and provide feedback, and in return will be offered a number of benefits, including first access to new knockout models and ordering priority and fulfillment, as well as participating in the establishment of the research and development pipeline for this technology.

"The real value of our knockout rat models will lie in the phenotypes that they display," commented Dr. Edward Weinstein, Director of SAGE Labs. "As a result, we are actively seeking experts in the field who are interested in the initial validation of these animals as part of our exclusive SAGE Priority Partners Program."

Initially, SAGE Labs will be working on knockout rat models that target over 20 genes across a number of research areas. One example is Neurobiology, where knockout rat models are being developed with conditions such as Schizophrenia, Parkinson's Disease, Obesity and Alzheimer's. The initial portfolio of models for neuroscience applications includes:

  1. DISC 1 - Disrupted in Schizophrenia 1 - The DISC 1 protein plays a role in neuronal cell growth and movement and was originally identified through a family with prevalent history of schizophrenia and other neurological disorders. It is suspected to play a role not only in schizophrenia, but also in bipolar disorder and depression.
  2. ApoE - Apolipoprotein E - ApoE is an essential protein responsible for the production of normal triglyceride containing lipoprotein catabolism, vital for the breakdown and release of energy. While most importantly identified for its role in cardiovascular disease, variations in the ApoE gene have recently been implicated in Alzheimer's disease and atherosclerosis.
  3. Leptin - Leptin - Leptin is an adipose (fat) derived hormone that plays a role in appetite and metabolism, and is also a player in satiety signaling. This has led to its study and significant research into the role that neurological signaling plays in obesity.
  4. BDNF - Brain derived neurotrophic factor - The BDNF protein is a nerve growth factor found in the brain that acts by supporting existing neurons and encouraging the growth of new neurons. Defects in BDNF expression have been linked to Alzheimer's, Huntington's disease, depression, dementia, schizophrenia, and obsessive-compulsive disorder (OCD).

"Our recently announced SAGEspeed model creation platform enables us to develop animal models in about four to five months in both Rat and Mouse, which is about a third of the time it would take using an Embryo Stem Cell approach," continued Weinstein. "The models that we have developed thus far are really the tip of the iceberg in terms of the long-term potential for 'knockout' gene technology to offer viable, rapidly available animal models with specific genetic changes that are expected to enable researchers to better understand gene function and, based on that understanding, develop new therapeutic approaches."

Looking ahead, Sigma-Aldrich sees significant potential for applications that use ZFN technology to develop rodent models for most types of human disease that could theoretically reduce research times by years and thus save a significant number of lives.

Further information on the SAGE Priority Partners Program can be accessed online at www.sageresearchmodels.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. Sigma-Aldrich has customers in Life Science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service.

Cautionary Statement: This release contains forward-looking statements relating to future strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich, Sigma, SAGE, and CompoZr are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):